PDF(Pubmed)
Abstract：
UNASSIGNED: Ramucirumab, an anti-vascular endothelial growth factor receptor (VEGFR) monoclonal antibody (mAb), inhibits angiogenesis and reduces tumor activity. Programmed cell death-ligand 1 (PD-L1) might act upon VEGFR2 to induce cancer cell angiogenesis and metastasis. Herein, we investigated the efficacy of combining ramucirumab and paclitaxel according to the status of PD-L1 expression in patients with advanced gastric cancer (AGC).
UNASSIGNED: This analysis included AGC patients who received ramucirumab plus paclitaxel as 2nd line therapy between December 1, 2018, and February 28, 2022, at Samsung Medical Center. All patient data analyses included an evaluation of PD-L1 expression using the combined positive score (CPS). We analyzed the efficacy and the survival of patients according to their PD-L1 expression.
UNASSIGNED: We included 117 patients in this analysis, and 80 patients (68.4%) had a PD-L1 CPS of one or more, 37 (31.6%) had five or more, and 19 (16.2%) had ten or more scores. Progression-free survival (PFS) and overall survival (OS) did not differ significantly between patients with a PD-L1 CPS of less than one and one or more {PD-L1 <1% vs. PD-L1 ≥1%; PFS: median 3.6 months [95% confidence interval (CI): 2.4-4.8 months] vs. median 4.1 months (95% CI: 3.5-4.7 months), P=0.93; PD-L1 <1% vs. PD-L1 ≥1%; OS: median 7.0 months (95% CI: 5.4-8.6 months) vs. median 8.1 months (95% CI: 6.4-9.8 months), P=0.32}. PFS and OS did not differ significantly between patients with a PD-L1 CPS of less than 5 and 5 or more [PD-L1 <5% vs. PD-L1 ≥5%; PFS: 3.9 months (95% CI: 3.3-4.5 months) vs. 4.4 months (95% CI: 3.0-5.8 months), P=0.57; OS: 7.4 months (95% CI: 6.5-8.3 months) vs. 10.0 months (95% CI: 1.1-18.9 months), P=0.07]. Interestingly, with a PD-L1 CPS cutoff of 10, PFS and OS did differ significantly [PD-L1 <10% vs. PD-L1 ≥10%; PFS: 3.8 months (95% CI: 3.3-4.3 months) vs. 5.7 months (95% CI: 4.1-7.3 months), P=0.05; OS: 7.2 months (95% CI: 6.5-7.9 months) vs. 18.9 months (95% CI: 6.5-31.3 months), P=0.04].
UNASSIGNED: No biomarkers have been established to predict survival times after ramucirumab plus paclitaxel treatment. This analysis suggests that a PD-L1 CPS cutoff of 10 might be novel a biomarker to predict the survival of AGC patients treated with ramucirumab and paclitaxel.
UNASSIGNED: This analysis included AGC patients who received ramucirumab plus paclitaxel as 2nd line therapy between December 1, 2018, and February 28, 2022, at Samsung Medical Center. All patient data analyses included an evaluation of PD-L1 expression using the combined positive score (CPS). We analyzed the efficacy and the survival of patients according to their PD-L1 expression.
UNASSIGNED: We included 117 patients in this analysis, and 80 patients (68.4%) had a PD-L1 CPS of one or more, 37 (31.6%) had five or more, and 19 (16.2%) had ten or more scores. Progression-free survival (PFS) and overall survival (OS) did not differ significantly between patients with a PD-L1 CPS of less than one and one or more {PD-L1 <1% vs. PD-L1 ≥1%; PFS: median 3.6 months [95% confidence interval (CI): 2.4-4.8 months] vs. median 4.1 months (95% CI: 3.5-4.7 months), P=0.93; PD-L1 <1% vs. PD-L1 ≥1%; OS: median 7.0 months (95% CI: 5.4-8.6 months) vs. median 8.1 months (95% CI: 6.4-9.8 months), P=0.32}. PFS and OS did not differ significantly between patients with a PD-L1 CPS of less than 5 and 5 or more [PD-L1 <5% vs. PD-L1 ≥5%; PFS: 3.9 months (95% CI: 3.3-4.5 months) vs. 4.4 months (95% CI: 3.0-5.8 months), P=0.57; OS: 7.4 months (95% CI: 6.5-8.3 months) vs. 10.0 months (95% CI: 1.1-18.9 months), P=0.07]. Interestingly, with a PD-L1 CPS cutoff of 10, PFS and OS did differ significantly [PD-L1 <10% vs. PD-L1 ≥10%; PFS: 3.8 months (95% CI: 3.3-4.3 months) vs. 5.7 months (95% CI: 4.1-7.3 months), P=0.05; OS: 7.2 months (95% CI: 6.5-7.9 months) vs. 18.9 months (95% CI: 6.5-31.3 months), P=0.04].
UNASSIGNED: No biomarkers have been established to predict survival times after ramucirumab plus paclitaxel treatment. This analysis suggests that a PD-L1 CPS cutoff of 10 might be novel a biomarker to predict the survival of AGC patients treated with ramucirumab and paclitaxel.
摘要：
■Ramucirumab，抗血管内皮生长因子受体（VEGFR）单克隆抗体（mAb），抑制血管生成并降低肿瘤活性。程序性细胞死亡配体1（PD-L1）可能作用于VEGFR2以诱导癌细胞血管生成和转移。在这里，我们根据晚期胃癌(AGC)患者PD-L1表达状况,研究了雷莫西单抗和紫杉醇联合应用的疗效.
该分析包括2018年12月1日至2022年2月28日在三星医疗中心接受雷莫西单抗联合紫杉醇作为二线治疗的AGC患者。所有患者数据分析包括使用组合阳性评分(CPS)评估PD-L1表达。我们根据患者的PD-L1表达分析其疗效和生存。
■我们在这项分析中纳入了117名患者，80例患者（68.4%）有一个或多个PD-L1CPS，37（31.6％）有5个或更多，19分(16.2%)有10分或以上。无进展生存期(PFS)和总生存期(OS)在PD-L1CPS小于1和1或以上的患者之间没有显著差异{PD-L1<1%vs.PD-L1≥1%；PFS：中位数3.6个月[95%置信区间（CI）：2.4-4.8个月]vs.中位数4.1个月（95%CI：3.5-4.7个月），P=0.93；PD-L1<1%vs.PD-L1≥1%；OS：中位数7.0个月（95%CI：5.4-8.6个月）与中位数8.1个月（95%CI：6.4-9.8个月），P=0.32}。PD-L1CPS小于5和5或更高的患者之间的PFS和OS没有显着差异[PD-L1<5％vs.PD-L1≥5%；PFS：3.9个月（95%CI：3.3-4.5个月）与4.4个月（95%CI：3.0-5.8个月），P=0.57；OS：7.4个月（95%CI：6.5-8.3个月）与10.0个月（95%CI：1.1-18.9个月），P=0.07]。有趣的是,PD-L1CPS截止值为10时，PFS和OS确实存在显着差异[PD-L1<10％vs.PD-L1≥10%；PFS：3.8个月（95%CI：3.3-4.3个月）与5.7个月（95%CI：4.1-7.3个月），P=0.05；OS：7.2个月（95％CI：6.5-7.9个月）与18.9个月（95%CI：6.5-31.3个月），P=0.04]。
■尚未建立生物标志物来预测雷莫西单抗联合紫杉醇治疗后的生存时间。该分析表明，PD-L1CPS截止值为10可能是一种新的生物标志物，可以预测用雷莫西单抗和紫杉醇治疗的AGC患者的生存率。
该分析包括2018年12月1日至2022年2月28日在三星医疗中心接受雷莫西单抗联合紫杉醇作为二线治疗的AGC患者。所有患者数据分析包括使用组合阳性评分(CPS)评估PD-L1表达。我们根据患者的PD-L1表达分析其疗效和生存。
■我们在这项分析中纳入了117名患者，80例患者（68.4%）有一个或多个PD-L1CPS，37（31.6％）有5个或更多，19分(16.2%)有10分或以上。无进展生存期(PFS)和总生存期(OS)在PD-L1CPS小于1和1或以上的患者之间没有显著差异{PD-L1<1%vs.PD-L1≥1%；PFS：中位数3.6个月[95%置信区间（CI）：2.4-4.8个月]vs.中位数4.1个月（95%CI：3.5-4.7个月），P=0.93；PD-L1<1%vs.PD-L1≥1%；OS：中位数7.0个月（95%CI：5.4-8.6个月）与中位数8.1个月（95%CI：6.4-9.8个月），P=0.32}。PD-L1CPS小于5和5或更高的患者之间的PFS和OS没有显着差异[PD-L1<5％vs.PD-L1≥5%；PFS：3.9个月（95%CI：3.3-4.5个月）与4.4个月（95%CI：3.0-5.8个月），P=0.57；OS：7.4个月（95%CI：6.5-8.3个月）与10.0个月（95%CI：1.1-18.9个月），P=0.07]。有趣的是,PD-L1CPS截止值为10时，PFS和OS确实存在显着差异[PD-L1<10％vs.PD-L1≥10%；PFS：3.8个月（95%CI：3.3-4.3个月）与5.7个月（95%CI：4.1-7.3个月），P=0.05；OS：7.2个月（95％CI：6.5-7.9个月）与18.9个月（95%CI：6.5-31.3个月），P=0.04]。
■尚未建立生物标志物来预测雷莫西单抗联合紫杉醇治疗后的生存时间。该分析表明，PD-L1CPS截止值为10可能是一种新的生物标志物，可以预测用雷莫西单抗和紫杉醇治疗的AGC患者的生存率。
